Genedrive Share Discussion Threads

[snowy20] 29/7/2022 08:46

HCV ,AIHL ,POC . Time to release the RNS .Time to move back to a Quid .

[snowy20] 29/7/2022 08:44

Pharmacy nurse Kico Chan was among those who took part in who took part in the study in Tayside using Genedrive (inset) technoligy .

genedrive plc (@genedriveplc) / Twitter › genedriveplc
The first nurse-led trial using the Genedrive® HCV ID Kit providing same-day results for at-risk individuals via pharmacies #GDR #HCV #genedrive

[spattow9] 28/7/2022 15:46

Don’t seem to get the latest updates on GDR do you have to pay extra for the info from various clients

[thecroots] 28/7/2022 14:23

Snowy,

News must be due. Two £2 trades in the last hour.

[snowy20] 28/7/2022 10:20

Has Time arrived for RNS .

Around 300 nurses are being trained to use the machine across MFT at Saint Mary’s Hospital, Wythenshawe Hospital, and North Manchester General Hospital, and the test is expected to be routinely used in all the hospitals’ neonatal units within weeks, which are part of Saint Mary’s Managed Clinical Service within the Trust.

[danessex] 28/7/2022 09:45

HAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHHAHAHAHAHAHAHAHAHAHHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHA

[snowy20] 28/7/2022 09:30

RNS this day . Next week .

[snowy20] 28/7/2022 09:22

ARE they filling large order .Will buy all my holding .Not able to buy .

[snowy20] 28/7/2022 08:58

Uxbridgearms .Not able to buy this day .Can sell all of my holding at 18.70

[danessex] 27/7/2022 16:08

18.27 sold lol

[uxbridgearms] 27/7/2022 15:28

Snowy, I think something is about to happen here I have not been able to buy all day.

[snowy20] 27/7/2022 08:52

Buyers active first hour .

[snowy20] 27/7/2022 08:45

Well financed this year. approx £6 million in bank number months past. NHS AIHL RNS even this week or soon ,Good chance Back to a quid .

[snowy20] 27/7/2022 08:38

Minister for Innovation, Lord Kamall, said: “Genomics is changing the future of healthcare – from detecting new variants of Covid to enabling more targeted treatment of illness.

“This innovative new test has the potential to prevent life altering and preventable side effects for babies and keep the NHS ahead of the curve in delivering state of the art care.

“The UK continues to lead the way in genomics expertise and is paving the way for earlier diagnosis of conditions in children and faster access to the right treatment”.

[snowy20] 27/7/2022 08:37

David Budd, CEO of Genedrive, said: “There is a significant drive within the NHS to alert healthcare professionals to the impact of antibiotic-induced hearing loss and encourage them to consider genetic testing prior to initiation of treatment.

“It’s a great example of using human genetics to guide specific therapy, which is now taking front and centre in clinical management globally. The application of Genedrive’s technology shows how a rapid, affordable, point-of-care test could impact patients’ treatment and quality of life across this as well as a wide range of fields”.

[snowy20] 27/7/2022 08:36

Mike Hobday, Director of Policy and Campaigns at the National Deaf Children’s Society, said: “The National Deaf Children’s Society welcomes the publication of this important study. The introduction of a rapid test to identify susceptibility to deafness caused by the antibiotic gentamicin will be greatly valued by many families of newborn babies.

“Up to now the genetic test has taken too long to return from the lab to be useful for babies requiring urgent treatment but a rapid test will be a game-changer”.

[snowy20] 27/7/2022 08:34

Professor Dame Sue Hill, Chief Scientific Officer for England and Senior Responsible Officer for Genomics in the NHS, said: “Genomic medicine is transforming healthcare, and this is a powerful example of how genetic testing can now be done extremely quickly and become a vital part of triage – not only in intensive care but across our services.

“It also shows the importance of thinking about how advances in technology can rapidly transform how we use genomics closer to care for our patients.”

Professor Newman, who is Associate Lead, Hearing Health Genomic Solutions at NIHR Manchester Biomedical Research Centre (BRC), said the team had successfully transferred the accuracy of the machine in the lab to working effectively in a ward. At the same time, clinicians adapted quickly to incorporate the test into their routine care for very sick children in the neonatal ward.

The idea for the test came five years ago, and trials started in 2020 with further adaptations and fine-tuning so that the current machine, which is called the Genedrive System, is now fully CE certified to be used in a clinical setting.

Study results were published in JAMA Pediatrics – the top-ranked paediatrics journal in the world – last week.

Backed by £900,000 funding from the National Institute for Health Research (NIHR) and support from the charity Royal National Institute for Deaf People, the Genedrive System, which costs £80 per baby, was developed by Genedrive, a start-up based at the University of Manchester. It was developed in close collaboration with Professor Newman’s team at Manchester Biomedical Research Centre.

[snowy20] 27/7/2022 08:28

A world-first genetic test that could save the hearing of hundreds of babies each year has been developed and successfully piloted in the NHS.

Taking just 25 minutes, the bedside machine identifies whether a critically ill baby admitted to intensive care has a gene that could result in permanent hearing loss if they are treated with a common emergency antibiotic.

The new swab test technique would replace a test that traditionally took several days and could save the hearing of 180 babies in England alone every year.

People admitted to intensive care are usually given an antibiotic called Gentamicin within 60 minutes. While Gentamicin is used to safely treat about 100,000 babies a year, one in 500 babies carry the gene that can make it cause permanent hearing loss.

Developed in Manchester, the new test means that babies found to have the genetic variant can be given an alternative antibiotic within the ‘golden hour.’

It is expected the test could save the NHS £5 million every year by reducing the need for other interventions, such as cochlear implants.

[snowy20] 27/7/2022 08:25

Moving up buyers loading up .Buyers moving in before next RNS .

[danessex] 26/7/2022 16:46

Oh dear lolllllll

[thecroots] 26/7/2022 14:04

I don't think he is snowy - you can understand english right?